

1 **Research Article**

2 **Treatment with an Anti-CK2 Synthetic Peptide Improves Clinical**
3 **Response in Covid-19 Patients with Pneumonia. A Randomized and**
4 **Controlled Clinical Trial**

5 Leticia R. Cruz ^{1*}, Idania Baladrón ^{2*}, Aliusha Rittoles ¹, Pablo A. Díaz ², Carmen Valenzuela ³,
6 Raúl Santana ¹, Maria M. Vázquez ², Ariadna García ¹, Deyli Chacón ¹, Delvin Thompson ¹,
7 Gustavo Perera ¹, Ariel González ⁴, Rafael Reyes ⁵, Loida Torres ⁴, Jesus Pérez ¹, Yania Valido ¹,
8 Ralysmay Rodriguez ¹, Dania M. Vázquez ², Mauro Rosales ^{2,6}, Ailyn C. Ramón ², George V.
9 Pérez ², Gerardo Guillén ², Verena Muzio ², Yasser Perera ^{2,7}, and Silvio E. Perea ² for the
10 ATENEA-Co-300 group♣

11 * These authors contributed equally to this work

- 12 1. Central Hospital “Luis Diaz Soto”, Havana 19130, Cuba
13 2. Center for Genetic Engineering and Biotechnology, Havana 10600, Cuba
14 3. Center for Molecular Immunology, Havana 11600, Cuba
15 4. International Center of Health “La Pradera”, Havana 11600, Cuba
16 5. National Institute of Oncology and Radiobiology, Havana 10400, Cuba
17 6. Faculty of Biology, University of Havana, Havana 10400, Cuba
18 7. China-Cuba Biotechnology Joint Innovation Center (CCBJIC), Yongzhou Zhong Gu
19 Biotechnology Co., Ltd, Yangjiaqiao Street, Lengshuitan District, Yongzhou City, Hunan
20 425000, China

21 **Corresponding Author:**

22 Silvio E. Perea, PhD, Prof (silvio.perea@cigb.edu.cu)
23 Head of the Molecular Oncology Group
24 Biomedical Research Area
25 Center for Genetic Engineering and Biotechnology
26 Havana 10600, Cuba

27 **Number of Figures:** 2

28 **Number of Tables:** 1

29

30 **Supplementary material:** 5

31 **Keywords:** Covid-19, SARS-Cov2, Protein Kinase CK2, CIGB-325

32 **ABSTRACT**

33 **Purpose:** The instrumental role of CK2 in the SARS-Cov2 infection has pointed out this
34 protein kinase as a promising therapeutic target in Covid-19. Anti-SARS-Cov2 activity
35 has been reported by CK2 inhibitors *in vitro*; however, any anti-CK2 clinical approach
36 has been investigated in Covid-19. This exploratory trial aimed to explore safety and
37 putative clinical benefit of CIGB-325, an anti-CK2 peptide previously assessed in cancer.

38 **Methods:** A monocentric, parallel group design, therapeutic exploratory trial of
39 intravenous CIGB-325 in adults hospitalized with Covid-19 was performed. Twenty
40 patients were randomly assigned to receive CIGB-325 (2.5 mg/kg/day during 5-
41 consecutive days) plus standard-of-care (10 patients) or standard-of-care (10 patients).
42 Adverse events were classified by the WHO Adverse Reaction Terminology. Parametric
43 and non-parametric statistical analyses were performed according to the type of variable.
44 Considering the small sample size, differences between groups were estimated by
45 Bayesian analysis.

46 **Findings:** CIGB-325 induced transient mild and/or moderate adverse events like pruritus,
47 flushing and rash in some patients. Both therapeutic regimens were similar respect to
48 SARS-Cov2 clearance in nasopharynx swabs over the time. However, CIGB-325
49 significantly reduced the median number of pulmonary lesions (9.5 to 5.5, $p = 0.042$) at
50 day 7 and proportion of patients with such effect was also higher according to Bayesian
51 analysis ($p_{Dif} > 0$; 0.951). Additionally, CIGB-325 significantly reduced the CPK ($p =$
52 0.007) and LDH ($p = 0.028$) plasma levels at day 7.

53 **Implications:** Our preliminary findings suggest that this anti-CK2 clinical approach
54 could be combined with standard-of-care in Covid-19 thus warranting larger studies.

55 INTRODUCTION

56 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide
57 and has infected nearly 20 million people [1, 2]. Many infected people are asymptomatic
58 or experience mild symptoms and recover without medical intervention [3, 4]. However,
59 older people and those with comorbid hypertension, diabetes, obesity, and heart disease
60 are at higher risk of life-threatening illness [5, 6]. Therefore, development of an effective
61 antiviral drug for COVID-19 is a global health priority. Along with the development of
62 new antiviral drugs, repurposing existing drugs for COVID-19 treatment is also
63 accelerated [7]. Some antiviral drugs have shown high efficacy against SARS-CoV-2
64 both *in vitro* [8] and *in vivo* models [9, 10]. A number of clinical studies such as
65 compassionate use programs and clinical trials have been conducted to test the efficacy of
66 FDA-approved drugs, such as lopinavir and ritonavir, chloroquine, favipiravir, and
67 remdesivir (RDV) [11-14]. More recently, a double-blind, randomized, placebo-
68 controlled trial of intravenous RDV in adults hospitalized with Covid-19 and lower
69 respiratory tract involvement had a median recovery time of 11 days (95% confidence
70 interval [CI], 9 to 12), as compared with 15 days (95% CI, 13 to 19) in those who
71 received placebo (rate ratio for recovery, 1.32; 95% CI, 1.12 to 1.55; $P < 0.001$) [15].

72 At present, the main antiviral strategies currently employed against SARS-CoV-2 can
73 broadly be divided into two types: strategies directly targeting the virus and strategies
74 indirectly targeting the virus via host modulation [16]. In both strategies there are
75 already-approved drugs and experimental candidates in Clinical trials [16]. Likewise,
76 discovery of novel cellular targets for SARS-Cov2 coronavirus has led to novel putative
77 clinical strategies which merit going into clinical research in Covid-19.

78 CK2 is a constitutively active Ser/Thr protein kinase deregulated in cancer and other
79 pathologies, responsible for about the 20% of the human phosphoproteome [17]. In
80 infectious diseases, CK2 phosphorylates and modulates the function of viral proteins
81 from Hepatitis C Virus (HCV), Vesicular stomatitis virus (VSV), Human
82 Immunodeficiency Virus (HIV), Human Papilloma Virus (HPV), and Herpes simplex-1
83 (HSV-1) [18]. Therefore, it is expected that pharmacological intervention with CK2 may
84 impact on in any step of viral life cycle. Recently, CK2 has been found to be directly
85 targeted by the SARS-Cov2 nucleocapsid protein and they both co-localize along the

86 filopodia protrusions that promote virus egress and rapid cell-to-cell spread across
87 epithelial mono-layers of infected cells [19]. Additionally, inhibition of CK2 in those
88 experiments demonstrated the instrumental role of this protein kinase for SARS-Cov2
89 infection *in vitro* [19].

90 Considering the scientific rationality of inhibiting CK2 in SARS-Cov2 infection and
91 taking advance of CIGB-325 (formerly CIGB-300) as an anti-CK2 synthetic peptide [20,
92 21] previously already assessed in different Phase I-II in cancer patients, we investigated
93 the putative clinical benefit of this peptide in Covid-19 patients. Particularly, safety and
94 tolerability of intravenous delivery of CIGB-325 has been previously assessed from 0.2
95 to 12.8 mg/kg [22, 23] as well as the consecutive-5 day regimen of administration.

96 Based on the FDA recommendations for Covid-19 developing drugs, we performed a
97 small and controlled clinical study [24]. In this exploratory study (proof-of-concept), we
98 administered intravenous CIGB-325 at 2.5 mg/kg along with standard-of-care for treating
99 SARS-Cov2 positive patients in Cuba which is based on alpha 2b-IFN plus
100 kaletra/hydroxyquinoline. Preliminary data indicated that combination of CIGB-325 with
101 standard-of-care improved chest-CT outcomes in Covid-19 patients with pneumonia at
102 day 7. Other signs of clinical benefit for this therapeutic regimen were also registered in
103 our study. This is the first clinical study where an anti-CK2 approach is explored in
104 Covid-19 disease and the preliminary data provided here could warrant larger studies.

105 **PATIENTS AND METHODS**

106 **Participants**

107 From June 1 to June 16, 2020, twenty patients confirmed as SARS-CoV-2 positive by
108 real-time transcriptase polymerase chain reaction (RT-PCR) were enrolled in a
109 monocentric parallel group design in therapeutic exploratory trial at the “Luis Diaz Soto”
110 Hospital in Havana, Cuba (<https://rpcec.sld.cu/trials/RPCEC00000317-En>, Code:
111 IG/CIGB300I/CV/2001, ATENEA-Co-300 trial). CIGB-300 code used for cancer
112 treatment was substituted by CIGB-325 just after the online registration of this clinical
113 trial; therefore, it appears labeled with the former code. The Ethics Committee for
114 Clinical Research in the hospital and Cuban Regulatory Agency (CECMED) approved
115 the trial. The study complied with the Good Clinical Practices and the precepts
116 established in the Declaration of the Helsinki World Medical Association. All patients
117 met the inclusion criteria described in the protocol and signed the informed consent.

118 **Laboratory examination**

119 Laboratory results included blood routine, leucocyte subsets and blood biochemical
120 parameters. Serum levels of CPK, LDH and RCP were determined by a specific Roche
121 system (Roche-cobas-C311).

122 **SARS-Cov2 viral dynamic in nasopharyngeal swabs**

123 Nasopharyngeal swabs were obtained from patients at days 0, 3, 7, and 14. Viral RNA
124 was detected by RT-PCR amplification by using specific SARS-Cov2 primers. Presence
125 of SARS-Cov2 in swabs was followed-up at indicated times and compared among both
126 groups.

127 **Clinical response**

128 Clinical status was classified as asymptomatic, mild, moderate and severe Covid-19
129 disease according to the NIH guide “Coronavirus Disease 2019 (COVID-19) Treatment
130 guidelines”. <https://www.covid19treatmentguidelines.nih.gov>. The chest-CT analysis was
131 performed considering number of pulmonary lesions, lesion’s extent and common Covid-
132 19 typical abnormalities like consolidation, glass-round opacity and mix pattern.

133 **Safety**

134 Pretreatment evaluation included a detailed history and physical examination. In addition,
135 hematological counts, blood chemistry, coagulation, radiography and chest-CT studies
136 were performed. Systemic toxicity was evaluated daily after each CIGB-325
137 administration. Severity of adverse events was classified by the WHO Adverse Reaction
138 Terminology. Causal relationship was classified as very probable (definitive), probable,
139 possible or remote (doubtfull).

140 **Statistical Analysis**

141 For chest-CT variables, the analysis was performed in Per Protocol population defined as
142 patients who completed the originally allocated and patients that have TAC at the
143 beginning and at the end of treatment. Continuous variables were expressed as mean and
144 standard deviations or median and interquartile ranges (depending of the assumption of
145 normal distribution). Student-t test or Mann-Whitney U test were applied to continuous
146 variables, and chi-square or Fisher's exact test were used for categorical variables. For
147 the variation in time in each group, Wilcoxon-rank test or Student-t test for dependent
148 variables were used. Type 1 error of 0.05 was specified. Considering the small sample
149 size, the difference between groups (for clinical and chest-CT evaluations, proportion of
150 patients with reduction of score and number of lesions) was estimated from the Bayesian
151 point of view, performing 10,000 simulations and specifying non-informative prior
152 distributions. The analysis was performed using SPSS 25.0 software and EPIDAT 3.1.

153 **RESULTS**

154 **Baseline characteristics of Covid-19 patients**

155 Between June 1, 2020, and June 16, 2020, twenty SARS-Cov2 positive patients
156 underwent randomization in the hospital “Luis Diaz Soto” in Havana, Cuba. A flowchart
157 of the study procedure is presented in Fig.1. Ten were assigned to receive intravenous
158 CIGB-325 + standard-of-care (Group I) and 10 to receive standard-of-care as control
159 (Group II). To diminish odds of severity, the Cuban National Program for managing
160 Covid-19 patients applies standard-of-care just upon confirmation of nasopharyngeal
161 SARS-Cov2 diagnosis irrespectively of having symptoms or not. The median number of
162 days between SARS-Cov2 diagnosis, hospitalization and treatment initiation was 2 days.
163 All the patients completed the treatment as planned except one patient from Group I who
164 experienced some concomitant moderate histaminergic adverse events during the first
165 CIGB-325 intravenous delivery and dose was decreased to 1.6 mg/kg for remaining days
166 as indicated in the clinical protocol.

167 Demographic characterizes among both groups were similar except the age. Fourteen
168 patients (70%) were asymptomatic at the enrollment and 9 (45%) at the starting day of
169 treatment. Overall, 25% of patients had hypertension, 25% had obesity and none had type
170 2 diabetes (Supp.1).

171 Data from baseline chest-CT analysis showed that 80% of patients in the CIGB-325
172 group had positive chest-CT according to presence of ground-glass opacity,
173 consolidation, mix pattern and affectation of more than three pulmonary lobules. The mix
174 pattern was the most predominant lesion. In the control group, 50% of patients had
175 positive chest-CT with presence of consolidation, mixed pattern and affectation of less
176 than two pulmonary lobules.

177 Concerning hematological and biochemical baseline parameters in all patients, abnormal
178 levels were observed in hemoglobin (25%), platelets (15%), neutrophils (50%),
179 lymphocytes (40%), aspartate aminotransferase (ASAT) (20%), alanine aminotransferase
180 (ALAT)(40%), ferritin (35%), creatinine (20%), and glycemia (30%). Other parameters
181 were in the normal range.

182 **Primary and exploratory efficacy end points**

183 The dynamic conversion from positive to negative of SARS-Cov2 RT-PCR results was
184 analyzed in both groups of treatments at 0, 3, 7, and 14 days. No significant differences
185 were observed in the median time, 11 days \pm 8.0 for CIGB-325 plus standard care and 12
186 days \pm 6 for standard care alone ($p = 0.614$). Thus, time to SARS-Cov2 viral clearance in
187 the nasopharynx swabs behaved similarly for both treatments over the time.

188 The clinical status was classified in categories of asymptomatic, mild, moderate or severe
189 disease and it was followed up until ending treatment and thereafter for both groups. In
190 the intent-*to-treat* population of CIGB-325 group at day 6 there were 2/10 patients that
191 remained asymptomatic since initiation of treatment, 2/10 changed from severe to
192 moderate, 1/10 from moderate to asymptomatic, 1/10 from mild to asymptomatic and
193 4/10 did not change their clinical status during the treatment. Otherwise, in the control
194 6/10 patients remained asymptomatic since initiation of treatment, 1/10 changed from
195 mild to asymptomatic and 3/10 did not change their clinical status during the treatment.

196 Additionally, chest-CT analysis was performed to investigate the effect of CIGB-325
197 over the Covid-19 pulmonary lesions. For that purpose, both number and lesion's extent
198 at day 0 and after treatment (day 7) were compared just in those patients analyzed per
199 protocol (Table 1). Importantly, CIGB-325 treatment significantly reduced the median
200 number of pulmonary lesions from 9.5 ± 10 (day 0) to 5.5 ± 10 (day 7) ($p = 0.042$).
201 Conversely, no substantial change was observed in the control group. Proportion of
202 patients with reduction of pulmonary lesions was higher in the CIGB-325 group
203 compared with control according to the Bayesian analysis ($pDif > 0; 0.951$) (Table 1).

204 The effect over lesion's extent showed in Supp. 2 including those patients analyzed per
205 protocol indicates that CIGB-325 treatment also reduced the median of lesion's extent
206 after consecutive-5 day regimen although not significantly. Otherwise, any kind of
207 reduction was observed in the control group. Importantly, proportion of patients with
208 reduction of lesion's extent was higher in the CIGB-325 group (4/7) compared with
209 control (1/9) ($pDif > 0; 0.982$) (Bayesian analysis).

210 The overall chest-CT response was also analyzed considering the lesion's extent and the
211 pattern of Covid-19 typical chest-CT abnormalities (Supp. 3). The analysis per protocol
212 showed that 50% (3/6) of patients in the CIGB-325 group had a favorable overall chest-

213 CT response compared with 28.6% (2/7) in the control (pDif > 0; 0.796) (Bayesian
214 analysis). Importantly, any patient had progression in the CIGB-325 group and 28.6%
215 (2/7) in the control group did it. Representative images of chest-CT evolution from one
216 CIGB-325 treated patient are shown in Fig. 2.

217 We also investigated the levels of Creatinine Phospho Kinase (CPK), Reactive C-Protein
218 (RCP), and Lactate dehydrogenase (LDH) in plasma. Of note, data from Supp. 4 shows
219 that CIGB-325 treatment significantly reduced the CPK (p = 0.007) and LDH (p = 0.028)
220 serum levels. Also, the RCP values were lowered by CIGB-325 although with no
221 statistical difference.

222 **Safety**

223 Data from safety analysis indicated that intravenous CIGB-325 added to standard-*of-care*
224 did increase both frequency of adverse events and patients with adverse events (Supp. 5).
225 Particularly, pruritus, flushing and rash were increased by CIGB-325 treatment in the
226 100, 80 and 60 % of patients respectively. As previously observed during CIGB-325
227 intravenous administration, intensity of this kind of adverse events was mild and/or
228 moderate in all of the patients.

229 **DISCUSSION**

230 Protein kinase CK2 has been recently suggested as a relevant target to combat SARS-
231 Cov2 infection because of its role on the viral particles egress once accumulated in
232 filopodial protrusions possessing budding viral particles [19]. Although anti-SARS-Cov2
233 activity has been demonstrated through *in vitro* models by inhibiting protein kinase CK2,
234 evidences of clinical benefit in Covid-19 for anti-CK2 approaches are not available at
235 this.

236 CIGB-325 is an anti-CK2 synthetic peptide extensively assessed in cancer patients whose
237 safety, tolerability and efficacy signs have been gathered from Phase I-II trials [22, 25].
238 This clinical trial investigated the short-term outcomes of intravenous CIGB-325 at 2.5
239 mg/kg in a consecutive-5 day regimen which was added to standard care used in Covid-
240 19 disease in Cuba. Preliminary results suggest a quick clinical benefit with CIGB-325
241 treatment particularly evidenced by the chest-CT data at day 7 post-treatment initiation.
242 Our trial found that this treatment regimen had clinical benefit for Covid-19 patients with
243 lower respiratory tract involvement. Specifically, CIGB-325 treatment fostered reduction
244 of both, the number pulmonary lesions, and lesion's extent at day 7. Likewise, proportion
245 of patients exhibiting this inhibitory effect is superior in the CIGB-325 group compared
246 with standard care. When overall chest-CT response was analyzed by gathering number
247 of lesions, lesion's extent and the pattern of Covid-19 typical abnormalities, 50% of
248 patients in the CIGB-325 group had favorable outcome compared with 20% in the
249 standard-of-care. The odds of difference for the CIGB-325 treatment respect standard
250 care were > 0.90 in all the chest-CT data by using a Bayesian model.

251 Recently, a clinical trial with RDV has reported clinical benefit in terms of the number of
252 days to recovery of the hospitalized Covid-19 patients with lower respiratory tract
253 involvement in 11 days (95% confidence interval [CI], 9 to 12) [15], however evidences
254 of chest-CT improvement at day 7 were not provided.

255 The chest-CT response observed in our trial could be explained by direct antiviral activity
256 of CIGB-325 in SARS-Cov2 infected pneumocytes [26]. Unpublished *in vitro* data from
257 our lab have documented anti-SARS-Cov2 effect of CIGB-325 in Vero-E6 cells.
258 Altogether, these findings further support an instrumental role of CK2 during SARS-
259 Cov2 infection [19].

260 The improvement of chest-CT response by addition of CIGB-325 to standard-of-care
261 could have a great clinical impact in avoiding progression to severity of Covid-19
262 patients. Additionally, our study shows that alpha 2b IFN + kaletra/hydroxychloroquine
263 also reduces pulmonary lesions at day 7 although to a lesser extent. Such effect rather
264 might be by the previously reported anti-SARS-Cov2 activity of type I IFNs when
265 administered either by parenteral route or inhaled [27].

266 On the other hand, several laboratory parameters may facilitate the assessment of disease
267 severity and rational triaging [28]. We found that CIGB-325 treatment decreased
268 significantly the CPK levels compared with standard care which can suggest an early
269 protective effect from tissue damage. Likewise, high serum CPK levels have been
270 associated to rhabdomyolysis, weakness and heart injury in Covid-19 patients; therefore,
271 these findings also support the clinical benefit of using CIGB-325 in this viral disease.
272 Importantly, LDH and CRP serum levels which are considered inflammatory markers
273 were also reduced after CIGB-325 treatment.

274 Improvement of the clinical status at day 7 also trended to be superior by adding CIGB-
275 325 to the standard-of-care where 50% (4/8) patients experienced change towards a more
276 favorable clinical category. Otherwise, standard-of-care alone improved clinical status in
277 25% (1/4).

278 The dynamic conversion from positive to negative of SARS-Cov2 RT-PCR at the
279 nasopharyngeal swabs was very similar for both groups of treatments over the time.
280 Addition of CIGB-325 to the standard care did not shorten the time to viral clearance
281 respect to the standard care at least in the regimen tested in our clinical trial. Other
282 protocols with higher frequency of CIGB-325 administration merit to be explored for that
283 purpose in future trials. Nonetheless, the usefulness and feasibility of the viral end point
284 in nasopharyngeal swabs to assess anti-SARS-Cov2 drugs has not been established yet.
285 Instead, clinical endpoints seem to be more informative in the Covid-19 disease [11, 15,
286 24]

287 The safety profile of CIGB-325 plus standard-of-care was very similar to that observed
288 for CIGB-325 alone in which a predominant pattern of transient histaminergic-like side
289 effects has been observed [22]. However, intensity of the side effects was mild and/or
290 moderate in all the patients and total resolution of them was achieved in no more than one

291 hour after CIGB-325 administration. Thus, our study revealed that combination of
292 intravenous CIGB-325 at 2.5 mg/kg with standard care for Covid-19 is a manageable and
293 safe strategy to treat patients with this infectious disease.

294 In this exploratory study with a small sample size, randomization allowed a balance
295 between the groups regarding the allocation of treatments but not regarding the
296 prognostic variables. Also, although the sample size in our study is too small to permit
297 generalizability, our data provide a window into what a larger trial might look like.

298 Finally, our study gave interesting clues suggesting a quick clinical benefit at day 7 by
299 using our anti-CK2 approach which has not been reported so far in Covid-19. Whether
300 CIGB-325 prevents COVID-19 getting worse by inducing an antiviral effect in the lungs
301 and preventing damage caused by the virus, is something that merit further investigation
302 in larger clinical trials.

303 **CONCLUSION**

304 Combination of CIGB-325 anti-CK2 peptide with alpha 2b-
305 IFN/kaletra/hydroxychloroquine was adequately tolerated and superior in improving
306 clinical and chest-CT response in Covid-19 patients as early as 7 days. SARS-Cov2
307 dynamics in nasopharyngeal swabs was similar for both treatments over the time. Our
308 clinical findings support future studies to continue to improve patient outcomes with
309 Covid-19 by optimizing CIGB-325 regimens and/or combining with other antiviral
310 agents.

311 **ACKNOWLEDGEMENTS**

312 We thank Elizeth García, José Luis Rodríguez, Grettel Melo, Reinier Hernandez, Marel Alonso,
313 Julio E Baldomero, and Francisco Hernandez from Clinical Department at the CIGB for their
314 great contribution in the clinical trial execution. Also, we thank the Covid-19 diagnosis service
315 from CIGB. This work was supported in part by the British Embassy in Havana with funds of the
316 International Programme of the Foreign, Commonwealth and Development Office (FCDO).

317 **DISCLOSURES**

318 The authors declare no conflict of interest.

319 **AUTHOR'S CONTRIBUTION**

320 **Conceptualization:** I.B, P.A.D, C.V, M.M.V, V.M, Y.P, S.E.P. **Methodology:** L.R.C, I.B,
321 P.A.D, M.M.V, R.S, A.G, D.C, D.T., L.T, J.P, V.M., D.M.V, Y.V, R.R, M.R, G.V.P., A.C.R,
322 Y.P., S.E.P. **Software:** R.H, M.A. **Validation:** I.B, C.V., G. P, A.G., R.R. **Formal analysis:** C.V.
323 **Investigation:** L.R.C, A.R., R.S, A.G, D.C, D.T, **Resources:** L.T, J.P, A.G.G, K.G., S.G,
324 M.E.F., J.F, Y.G, Y.A., R.P., L.P, R.M., M.P., D.G., Y.O.T, D.P.M, E.A.D, Y.M., C.A., Y.S.,
325 G.L. **Data curation:** I.E., M.G., S.M.M, R.H, M.A.. **Writing original draft:** S.E.P, C.V., I.B.
326 **Writing-Review and editing:** I.B, Y.P, M.R., L.D.R, P.A.D, C.V, S.E.P. **Visualization:** I.B,
327 C.V, Y.P, M.R, S.E.P. **Supervision:** I.B, P.A.D, M.M.V., V.M. **Project administration:** S.E.P,
328 I.B, G.G. **Funding acquisition:** G.G., S.E.P.

329 **APPENDIX**

330 ♣ATENEA-Co-300 group: Idelsis Esquivel, Maura García, Sara María Martínez, Ana Gloria
331 Galarraga, Kenia Gómez, Sidalyn Gutiérrez, Maria E Fuerte, Jane Fernández, Yose Gamallo,
332 Yanelis Alvarez, Yarelis Amador, Reynier Perez, Lisset Perurena, Rosa Martinez, Manuel Puerto,
333 Daimays González, Yahima de la O Tamayo, Dianelis Pérez-Malo, Estela A Deyvis, Yuilyns
334 Morales, Caridad Aguirre, Yuliet Sinclair, Reinier Hernández, Marel Alonso, Gilda Lemus.

335 **REFERENCES:**

- 336 1. [https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200809-covid-19-](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200809-covid-19-sitrep-202)
337 [sitrep-202.](https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200809-covid-19-sitrep-202)
- 338 2. <https://coronavirus.jhu.edu/map.html>.
- 339 3. Cohen, P. A.; Hall, L.; John, J. N.; Rapoport, A. B. In *The early natural history of SARS-CoV-2*
340 *infection: Clinical observations from an urban, ambulatory COVID-19 clinic*, Mayo Clinic
341 Proceedings, 2020; Elsevier: 2020; pp 1124-1126.
- 342 4. Wu, Z.; McGoogan, J., Outbreak in China: Summary of a Report of 72314 Cases from the Chinese
343 Center for Disease Control and Prevention. *JAMA* **2020**, *10*.
- 344 5. Wu, J.; Mafham, M.; Mamas, M.; Rashid, M.; Kontopantelis, E.; Deanfield, J.; de Belder, M.;
345 Gale, C. P., Place and underlying cause of death during the COVID19 pandemic: retrospective
346 cohort study of 3.5 million deaths in England and Wales, 2014 to 2020. *medRxiv* **2020**.
- 347 6. Phillips, R. O.; Robert, J.; Abass, K. M.; Thompson, W.; Sarfo, F. S.; Wilson, T.; Sarpong, G.;
348 Gateau, T.; Chauty, A.; Omollo, R., Rifampicin and clarithromycin (extended release) versus
349 rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-
350 inferiority phase 3 trial. *The Lancet* **2020**.
- 351 7. Pushpakom, S.; Iorio, F.; Eyers, P. A.; Escott, K. J.; Hopper, S.; Wells, A.; Doig, A.; Guilliams,
352 T.; Latimer, J.; McNamee, C., Drug repurposing: progress, challenges and recommendations.
353 *Nature reviews Drug discovery* **2019**, *18*, (1), 41-58.
- 354 8. Ohashi, H.; Watashi, K.; Saso, W.; Shionoya, K.; Iwanami, S.; Hirokawa, T.; Shirai, T.; Kanaya,
355 S.; Ito, Y.; Kim, K. S., Multidrug treatment with nelfinavir and cepharanthine against COVID-19.
356 *bioRxiv* **2020**.
- 357 9. Bao, L.; Deng, W.; Gao, H.; Xiao, C.; Liu, J.; Xue, J.; Lv, Q.; Liu, J.; Yu, P.; Xu, Y., Lack of
358 reinfection in rhesus macaques infected with SARS-CoV-2. *bioRxiv* **2020**.
- 359 10. Cao, B.; Wang, Y.; Wen, D.; Liu, W.; Wang, J.; Fan, G.; Ruan, L.; Song, B.; Cai, Y.; Wei, M., A
360 trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19. *New England Journal of*
361 *Medicine* **2020**.
- 362 11. Wang, Y.; Zhang, D.; Du, G.; Du, R.; Zhao, J.; Jin, Y.; Fu, S.; Gao, L.; Cheng, Z.; Lu, Q.,
363 Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled,
364 multicentre trial. *The Lancet* **2020**.
- 365 12. Borba, M. G. S.; Val, F. F. A.; Sampaio, V. S.; Alexandre, M. A. A.; Melo, G. C.; Brito, M.;
366 Mourão, M. P. G.; Brito-Sousa, J. D.; Baía-da-Silva, D.; Guerra, M. V. F., Effect of high vs low
367 doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute
368 respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial. *JAMA*
369 *network open* **2020**, *3*, (4), e208857-e208857.
- 370 13. Cai, Q.; Yang, M.; Liu, D.; Chen, J.; Shu, D.; Xia, J.; Liao, X.; Gu, Y.; Cai, Q.; Yang, Y.,
371 Experimental treatment with favipiravir for COVID-19: an open-label control study. *Engineering*
372 **2020**.
- 373 14. Bauchner, H.; Fontanarosa, P. B., Randomized clinical trials and COVID-19: managing
374 expectations. *Jama* **2020**.
- 375 15. Beigel, J. H.; Tomashek, K. M.; Dodd, L. E.; Mehta, A. K.; Zingman, B. S.; Kalil, A. C.;
376 Hohmann, E.; Chu, H. Y.; Luetkemeyer, A.; Kline, S., Remdesivir for the treatment of Covid-
377 19—preliminary report. *New England Journal of Medicine* **2020**.
- 378 16. Ahidjo, B. A.; Loe, M.; Ng, Y. L.; Mok, C. K.; Chu, J. J. H., Current Perspective of Antiviral
379 Strategies against COVID-19. *ACS Infectious Diseases* **2020**.
- 380 17. Meggio, F.; Pinna, L. A., One-thousand-and-one substrates of protein kinase CK2? *FASEB*
381 *journal : official publication of the Federation of American Societies for Experimental Biology*
382 **2003**, *17*, (3), 349-68.

- 383 18. Keating, J. A.; Striker, R., Phosphorylation events during viral infections provide potential
384 therapeutic targets. *Reviews in medical virology* **2012**, 22, (3), 166-81.
- 385 19. Bouhaddou, M.; Memon, D.; Meyer, B.; White, K. M.; Rezelj, V. V.; Marrero, M. C.; Polacco, B.
386 J.; Melnyk, J. E.; Ulferts, S.; Kaake, R. M., The global phosphorylation landscape of SARS-CoV-
387 2 infection. *Cell* **2020**, 182, (3), 685-712. e19.
- 388 20. Perea, S. E.; Reyes, O.; Puchades, Y.; Mendoza, O.; Vispo, N. S.; Torrens, I.; Santos, A.; Silva,
389 R.; Acevedo, B.; López, E.; Falcón, V.; Alonso, D. F., Antitumor effect of a novel proapoptotic
390 peptide that impairs the phosphorylation by the protein kinase 2 (casein kinase 2). *Cancer Res*
391 **2004**, 64, (19), 7127-9.
- 392 21. Perera, Y.; Ramos, Y.; Padrón, G.; Caballero, E.; Guirola, O.; Caligiuri, L. G.; Lorenzo, N.;
393 Gottardo, F.; Farina, H. G.; Filhol, O., CIGB-300 anti-cancer peptide regulates the protein kinase
394 CK2-dependent phosphoproteome. *Mol Cell Biochem* **2020**.
- 395 22. García-Diegues, R.; de la Torre-Santos, A., Phase I Study of CIGB-300 Administered
396 Intravenously in Patients with Relapsed/Refractory Solid Tumors. *ARCHIVOS DE MEDICINA*
397 **2018**, 1, (1), 4.
- 398 23. Fernández Águila, J. D.; García Vega, Y.; Ríos Jiménez, R. O.; López Sacerio, A.; Rodríguez
399 Rodríguez, C. R.; Rodríguez Fraga, Y.; Valenzuela Silva, C., Safety of intravenous application of
400 cigb-300 in patients with hematological malignancies. EHPMA study. *Revista Cubana de*
401 *Hematología, Inmunología y Hemoterapia* **2016**, 32, (2), 236-248.
- 402 24. <https://www.fda.gov/drugs/guidance-compliance-regulatory-information/guidances-drugs>.
- 403 25. Perea, S. E.; Baladrón, I.; Valenzuela, C.; Perera, Y., CIGB-300: A peptide-based drug that
404 impairs the Protein Kinase CK2-mediated phosphorylation. *Semin Oncol* **2018**, 45, (1-2), 58-67.
- 405 26. Carsana, L.; Sonzogni, A.; Nasr, A.; Rossi, R. S.; Pellegrinelli, A.; Zerbi, P.; Rech, R.; Colombo,
406 R.; Antinori, S.; Corbellino, M., Pulmonary post-mortem findings in a series of COVID-19 cases
407 from northern Italy: a two-centre descriptive study. *The Lancet Infectious Diseases* **2020**.
- 408 27. Pereda, R.; Gonzalez, D.; Rivero, H. B.; Rivero, J. C.; del Rosario Lopez, L.; Mezquia, N.;
409 Venegas, R.; Betancourt, J. R.; Dominguez, R. E., Therapeutic effectiveness of interferon alpha 2b
410 treatment for COVID-19 patient recovery. *medRxiv* **2020**.
- 411 28. Velavan, T. P.; Meyer, C. G., Mild versus severe COVID-19: Laboratory markers. *International*
412 *Journal of Infectious Diseases* **2020**, 95, 304-307.

FIGURE AND TABLES




Figure 1: Randomization and enrollment.




Figure 2: Chest-CT Evolution. Representative chest-CT images from one patient in the CIGB-325 group at day 0 and 7.

		Group	I	II	Sign. (U-Mann Whitney)
		N*	6	7	
Number of lesions	Day 0	Median ± RI	9.5 ± 10.0	3.0 ± 5.0	0.051
		(Min; Max)	(0; 18)	(0; 10)	
	Day 7	Median ± RI	5.5 ± 10.0	2.0 ± 5.0	0.149
		(Min; Max)	(0; 17)	(0; 6)	
		Sign. (Wilcoxon)	0.042	0.680	
Reduction of lesions	YES		5 (83.3%)	3 (42.9%)	0.266 (Fisher)
	NO		1 (16.7%)	4 (57.1%)	
	Dif. (IC 95%)		41.4 (-6.9; 78.6)		Bayesian analysis
	P (Dif.>0)		0.951		

* Per protocol population defined as patients who completed the originally allocated and patients that have TAC at the beginning and at the end of treatment.

SUPPLEMENTARY MATERIALS


Supplementary 1. Demographic and Clinical Characteristics at Baseline			
Characteristic	All (N=20)	CIGB-325 + Standard Care (N=10)	Standard Care (N=10)
Age (years)	45.35±12.0	51.6±11.4	39.1±12.6
Sex No. (%)			
Male	14 (70)	8 (80)	6 (60)
Female	6 (30)	2 (20)	4 (40)
Skin color No. (%)			
White	12 (60)	5 (50)	7 (70)
Mestizo	2 (20)	1 (10)	1 (10)
Black	6 (20)	4 (40)	2 (20)
Coexisting conditions No./Total No. (%)			
Hypertension	5 (25)	5 (50)	0 (0.0)
Obesity	5 (25)	2 (20)	3 (30)
Type 2 Diabetes	0 (0.0)	0 (0.0)	0 (0.0)
Cancer	1 (5)	1 (10)	0 (0.0)
Iron deficiency Anemia	1 (5)	0 (0.0)	1 (10)
Hypothyroidism	1 (5)	0 (0.0)	1 (10)
Glaucoma	1 (5)	0 (0.0)	1 (10)
Clinical status at enrollment			
Asymptomatic	14 (70)	6 (60)	8 (80)
Symptomatic	6 (20)	4 (40)	2 (20)
Clinical status at the starting day of treatment			
Asymptomatic	9 (45)	3 (30)	6 (60)
Mild	0 (0.0)	0 (0.0)	0 (0.0)
Moderate	9 (45)	5 (50)	4 (40)
Severe	2 (10)	2 (20)	0 (0.0)
Symptoms			
Headache	3 (15)	2 (20)	1 (10)
Anosmia	1 (5)	0 (0.0)	1 (10)
Loss of taste	1 (5)	0 (0.0)	1 (10)
Fever	2 (10)	2 (20)	0 (0.0)
Dry cough	2 (10)	1 (10)	1 (10)
Loss of appetite	1 (5)	1 (10)	0 (0.0)
Shortness of breath	1 (5)	0 (0.0)	1 (10)
Diarrhea	1 (5)	1 (10)	0 (0.0)

Supplementary 2: Chest-CT evolution considering lesion's extent					
		Group	I	II	Sign. (U-Mann Whitney)
		N*	7	9	
Lesion's extent (Score 1-5)	Day 0	Median ± RI	4.5 ± 10.0	2.0 ± 5.0	0.146
		(Min; Max)	(0; 18)	(0; 6)	
	Day 7	Median ± RI	3.5 ± 10.0	2.0 ± 3.0	0.189
		(Min; Max)	(0; 15)	(0; 6)	
		Sign. (Wilcoxon)	0.066	1.000	
Reduction of lesion's extent	YES		4 (66.7%)	1 (14.3%)	0.103 (Fisher)
	NO		2 (33.0%)	6 (85.7%)	
	Dif. (IC 95%)		53.2 (3.6; 86.8)		Bayesian analysis
	P (Dif.>0)		0.982		

* Per protocol population defined as patients who completed the originally allocated and patients that have TAC at the beginning and at the end of treatment

Supplementary 3: Overall chest-CT response						
Group		I		II		Sig. (Fisher)
N		Frequency	%	Frequency	%	
Chest-CT response	N*	10	100.0	10	100.0	0.592
	Responders	6	60.0	7	70.0	
	No progression	3	50.0	2	28.6	
	Stable	1	16.7	2	28.6	
	Progression	2	33.3	1	14.3	
		Progression	0	0.0	2	28.6
	Dif. (IC 95%)	21.0 (-28.6; 66.0)				Bayesian analysis
	P (Dif.>0)	0.796				

* Per protocol population defined as patients who completed the originally allocated and patients that have TAC at the beginning and at the end of treatment.



Supplementary 4: Serum levels of Covid-19 linked markers. Serum levels of CPK (A), RCP (B) and LDH (C). Group I: CIGB-325 + Standard-of-care. Group II: Standard-of-care.

Supplementary 5: Adverse events								
	Group I				Group II			
	Patients		Events		Patients		Events	
	Frequency	%	Frequency	%	Frequency	%	Frequency	%
N	10	100	109	100	10	100	7	100
Pruritus	10	100.0	48	44.0	--	--	--	--
Rash	6	60.0	12	11.0	--	--	--	--
Flush	8	80.0	23	21.1	--	--	--	--
Hot flashes	5	50.0	12	11.0	--	--	--	--
Wheals	3	30.0	5	4.6	--	--	--	--
Bradycardia	1	10.0	1	0.9	--	--	--	--
Cramps	2	20.0	2	1.8	1	10.0	1	14.3
Trembling	2	20.0	2	1.8	--	--	--	--
Chills	1	10.0	1	0.9	--	--	--	--
Nausea	1	10.0	1	0.9	1	10.0	2	28.6
Tinnitus	1	10.0	2	1.8	--	--	--	--
Diarrhea	--	--	--	--	1	10.0	2	28.6
Headache	--	--	--	--	1	10.0	2	28.6

Group I: CIGB-325 plus standard-of-care Group II: Standard-of-care